ATRIAL-FIBRILLATION AND FLUTTER - MAINTAINING STABILITY OF SINUS RHYTHM VERSUS VENTRICULAR RATE CONTROL

被引:13
作者
ANTMAN, EM
机构
[1] Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
关键词
ATRIAL FIBRILLATION; SINUS RHYTHM; ANTIARRHYTHMIC THERAPY; CLINICAL TRIALS;
D O I
10.1111/j.1540-8167.1995.tb00372.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Two major treatment strategies have emerged for managing atrial fibrillation: maintaining sinus rhythm by chronic administration of suppressive antiarrhythmic agents versus controlling the ventricular rate and chronic anticoagulation. Potential benefits of maintenance of sinus rhythm include improvement of the hemodynamic profile of the patient, a decreased risk of cerebrovascular accidents, reduced symptoms, and, if atrial fibrillation is successfully suppressed, possible elimination of the need for chronic anticoagulation. When selecting long-term antiarrhythmic drug therapy for suppression of atrial fibrillation, it should be recalled that at least 50% of patients have a recurrence of the arrhythmia within the first year and the majority of other patients have a recurrence within the next 3 to 5 years. In addition, the risk of proarrhythmia and sudden cardiac death must be considered; this has stimulated interest in nonpharmacologic approaches to maintaining sinus rhythm. Large multicenter randomized trials are now under way to compare the benefits and risks of maintaining sinus rhythm versus controlling the ventricular rate and chronically anticoagulating patients in atrial fibrillation. Important endpoints of these trials include mortality, functional capacity, and quality of life.
引用
收藏
页码:962 / 971
页数:10
相关论文
共 76 条
[1]   LEFT-VENTRICULAR FUNCTION IN PATIENTS WITH ATRIAL-FIBRILLATION BEFORE AND AFTER CARDIOVERSION [J].
ALAM, M ;
THORSTRAND, C .
AMERICAN JOURNAL OF CARDIOLOGY, 1992, 69 (06) :694-696
[2]  
ALLESSIE M, 1995, AM HEART MONOGR S, P155
[3]  
ALLESSIE MA, 1987, CARDIAC ARRHYTHMIAS, P186
[4]  
ALLESSIE MA, 1992, ATRIAL FIBRILLATION, P59
[5]  
ALLESSIE MA, 1987, CARDIAC ARRHYTHMIAS, P67
[6]   ATRIAL-FIBRILLATION - NATURAL-HISTORY, COMPLICATIONS, AND MANAGEMENT [J].
ALPERT, JS ;
PETERSEN, P ;
GODTFREDSEN, J .
ANNUAL REVIEW OF MEDICINE, 1988, 39 :41-52
[7]   PREVENTION OF SYMPTOMATIC RECURRENCES OF PAROXYSMAL ATRIAL-FIBRILLATION IN PATIENTS INITIALLY TOLERATING ANTIARRHYTHMIC THERAPY - A MULTICENTER, DOUBLE-BLIND, CROSSOVER STUDY OF FLECAINIDE AND PLACEBO WITH TRANSTELEPHONIC MONITORING [J].
ANDERSON, JL ;
GILBERT, EM ;
ALPERT, BL ;
HENTHORN, RW ;
WALDO, AL ;
BHANDARI, AK ;
HAWKINSON, RW ;
PRITCHETT, ELC .
CIRCULATION, 1989, 80 (06) :1557-1570
[8]  
ANDERSON JL, 1988, AM J CARDIOL, V62, pD62
[9]  
[Anonymous], 1994, ARCH INTERN MED, V154, P1449
[10]   THERAPY OF REFRACTORY SYMPTOMATIC ATRIAL-FIBRILLATION AND ATRIAL-FLUTTER - A STAGED CARE APPROACH WITH NEW ANTIARRHYTHMIC DRUGS [J].
ANTMAN, EM ;
BEAMER, AD ;
CANTILLON, C ;
MCGOWAN, N ;
FRIEDMAN, PL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1990, 15 (03) :698-707